COTL1 Protein Regulating Hematopoietic Stem Cell Homeostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively diagnose and treat blood-related diseases caused by abnormalities in hematopoietic stem cell homeostasis, particularly due to mutations or decreased expression of the COTL1 gene or protein, which affect mitochondrial dynamics and energy metabolism.
Innovation Solution
A method involving measuring the expression level of the COTL1 gene or protein in biological samples and comparing it to control samples for diagnosis, and using pharmaceutical compositions containing COTL1 protein or its vector, or inhibitors of COTL1 expression/activity to treat blood-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used for blood-related diseases, then general blood cell counting and basic morphology assessment can be performed, but accurate diagnosis of diseases caused by COTL1 gene mutations or decreased expression is not achievable
Solution Approach 1:
The patent introduces COTL1-specific antibodies as intermediary detection tools that specifically bind to COTL1 protein. These antibodies serve as mediators between the target antigen (COTL1 protein) and detection systems, enabling precise measurement of COTL1 expression levels and identification of mutations that would otherwise be undetectable by conventional methods
Solution Approach 2:
The patent replaces conventional mechanical/cellular blood analysis methods with immunological detection systems using COTL1-specific antibodies. This substitution enables molecular-level detection of COTL1 protein expression and characteristics, achieving diagnostic precision for COTL1-related blood diseases that cannot be obtained through traditional blood cell counting and morphology assessment
2Reliability
If allogeneic hematopoietic stem cell transplantation is performed, then treatment of intractable blood-related diseases can be achieved, but the complexity and risk of the procedure increases
Solution Approach 1:
The patent enables preliminary diagnosis and characterization of COTL1-related blood diseases through specific detection methods using COTL1 antibodies. By identifying COTL1 expression levels, mutations, and cellular characteristics before transplantation, the system allows for better patient selection, treatment planning, and risk assessment, thereby improving treatment reliability while managing procedural complexity
Solution Approach 2:
The patent establishes a feedback mechanism where COTL1-specific detection methods provide detailed information about disease characteristics, cellular differentiation status, and mitochondrial function. This feedback enables clinicians to optimize transplantation strategies, monitor treatment response, and adjust therapeutic approaches based on precise molecular and cellular profiles of the patient's condition
3Reliability
If COTL1 protein expression is decreased or mutated, then hematopoietic stem cell homeostasis is disrupted leading to blood-related diseases, but conventional treatments do not address the underlying cause
Solution Approach 1:
The patent employs COTL1-specific antibodies as intermediary detection tools that specifically recognize and bind to COTL1 protein. These antibodies enable direct detection and quantification of COTL1 expression levels, identification of COTL1 mutations, and assessment of COTL1-related cellular abnormalities, providing the means to detect and measure the underlying cause of blood-related diseases that conventional methods cannot identify
Solution Approach 2:
The patent enables detection and measurement of specific parameters related to COTL1 function, including COTL1 protein expression levels, cellular differentiation markers, and mitochondrial membrane potential. By monitoring these parameters, the system can directly assess the impact of COTL1 mutations or decreased expression on hematopoietic stem cell homeostasis and respond with targeted therapeutic interventions
Data Source
AI summary
A COTL1 gene or protein maintains and regulates the homeostasis of hematopoietic stem cells. A method of diagnosis and treatment of blood-related disease caused either by abnormalities in the homeostasis of hematopoietic stem cells, which result from a mutation in the COTL1 gene or a decrease in the expression of the COTL1 protein, or by an imbalance between the differentiation or proliferation and damage or death of hematopoietic stem cells, or by abnormalities in mitochondrial homeostasis are disclosed. The COTL1 gene or protein plays an important role in regulating mitochondrial morphology, and when it is knocked down, the number of hematopoietic stem cells decreases.